124467-23-8

Basic information

• Product Name: 2-Chloro-8-fluoroquinoline
• Synonyms: 2-Chloro-8-fluoroquinoline
• CAS NO: 124467-23-8
• Molecular Formula: C₉H₅ClFN
• Molecular Weight: 181.5941032
• Mol File: 124467-23-8.mol
• Article Data: 4

Chemical Properties

• Melting Point: 82-84℃
• Boiling Point: 271.3±20.0 °C(Predicted)
• Appearance: /
• Density: 1.366±0.06 g/cm3(Predicted)
• Storage Temp.: Room temperature.
• PKA: -2.73±0.50(Predicted)
• CAS DataBase Reference: 2-Chloro-8-fluoroquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-8-fluoroquinoline(124467-23-8)
• EPA Substance Registry System: 2-Chloro-8-fluoroquinoline(124467-23-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 124467-23-8(Hazardous Substances Data)

Usage

General Description

2-Chloro-8-fluoroquinoline is a chemical compound with the molecular formula C9H5ClFN. It is a quinoline derivative that contains both chlorine and fluorine substituents. 2-Chloro-8-fluoroquinoline exhibits antimicrobial and antiparasitic properties, making it valuable for pharmaceutical and medicinal applications. It is also used in the production of agrochemicals and specialty chemicals. The compound's structure and reactivity make it a versatile building block for the synthesis of various organic compounds and may have potential as a starting material for the development of new drugs. However, it is important to handle and use 2-Chloro-8-fluoroquinoline with care, as it may be harmful if not properly managed.

Upstream product

• 612-62-4 2-Chloroquinoline 
• 348-54-9 2-Fluoroaniline 
• 1065481-24-4 (2E)-N-(2-fluorophenyl)-3-phenylprop-2-enamide 
• 71738-83-5 2-hydroxy-8-fluoroquinoline 
• 71738-83-5 8-fluoroquinolin-2(1H)-one 

Downstream Products

• 1065481-27-7 (R)-1-(2-chloro-8-fluoroquinolin-3-yl)ethanol 
• 1464832-35-6 2-((1S)-1-(8-fluoro-2-(2-(methylthio)phenyl)quinolin-3-yl)ethyl)isoindoline-1,3-dione 
• 1464832-37-8 2-((1S)-1-(8-fluoro-2-(2-(methylsulfonyl)phenyl)-3-quinolinyl)ethyl)-1H-isoindole-1,3(2H)-dione 
• 1464832-39-0 (1S)-1-(8-fluoro-2-(2-(methylsulfonyl)phenyl)-3-quinolinyl)ethanamine 
• 1464832-30-1 4-amino-6-(((1S)-1-(8-fluoro-2-(2-(methyl-sulfonyl)phenyl)-3-quinolinyl)ethyl)amino)-5-pyrimidinecarbonitrile 
• 1065478-86-5 N-((S)-1-(8-fluoro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine 
• 1065481-30-2 (1S)-1-(8-fluoro-2-(3-fluorophenyl)quinolin-3-yl)ethanamine 
• 1065481-29-9 3-((S)-1-azidoethyl)-8-fluoro-2-(3-fluorophenyl)quinoline 
• 1065481-28-8 (S)-3-(1-azidoethyl)-2-chloro-8-fluoro-quinoline 
• 71738-83-5 2-hydroxy-8-fluoroquinoline 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on, or associated with p110 activity, including but not restricted to leukemias, such as acute myeloid leukaemia (AML), myelo-dysplastic syndrome (MDS), myelo-proliferative diseases (MPD), chronic myeloid leukemia (CML), T-cell acute lymphoblastic leukaemia (T-ALL), B-cell acute lymphoblastic leukaemia (B-ALL), non Hodgkins lymphoma (NHL), B-cell lymphoma and solid tumors, such as breast cancer.